日韩欧美 a级,国产又色又爽又刺激在线观看,偷偷色噜狠狠狠狠的777米奇,浮妇高潮喷白浆视频

歡迎光臨源葉生物,登錄 | 注冊(cè) |
當(dāng)前位置: 首頁 > 小分子抑制劑 > Membranetransporter/Ionchannel > Tenapanor

瀏覽歷史

S82509

Tenapanor

源葉(MedMol) 98%
  • 英文名:
  • Tenapanor
  • 別名:
  • CAS號(hào):
  • 1234423-95-0
  • 分子式:
  • C50H66Cl4N8O10S2
  • 分子量:
  • 1145.049
品牌貨號(hào)產(chǎn)品規(guī)格價(jià)格(RMB) 庫存(上海) 北京 武漢 南京 數(shù)量計(jì)量單位 加入購(gòu)物車...
源葉(MedMol) S82509-5mg 98% ¥740.00元 預(yù)計(jì)交期:2-3天 - - - EA 加入購(gòu)物車
源葉(MedMol) S82509-10mg 98% ¥1180.00元 預(yù)計(jì)交期:2-3天 - - - EA 加入購(gòu)物車
源葉(MedMol) S82509-25mg 98% ¥2450.00元 預(yù)計(jì)交期:2-3天 - - - EA 加入購(gòu)物車
大包裝詢價(jià)

提交您的電話號(hào)碼并同意《個(gè)人信息授權(quán)與保護(hù)申明》,到貨后將短信提示。
提交

產(chǎn)品介紹

參考文獻(xiàn)

質(zhì)檢證書(COA)

摩爾濃度計(jì)算器

相關(guān)產(chǎn)品

  • 提示:詳情請(qǐng)下載說明書。
  • 產(chǎn)品描述: Tenapanor (AZD1722) is a potent and orally active sodium/hydrogen exchanger isoform 3 (NHE3) inhibitor. Tenapanor reduces intestinal phosphate absorption predominantly through reduction of passive paracellular phosphate flux. Tenapanor has the potential for the research of hyperphosphatemia
  • 靶點(diǎn): IC50: 5 nM (NHE3, human), 10 nM (NHE3, rat);SodiumChannel
  • 體內(nèi)研究:
    Tenapanor (0.15, 0.5 mg/kg; p.o.) reduces passive paracellular phosphate absorption in rats. Tenapanor (0.15 mg/kg; p.o.; twice-daily for 11 consecutive days) increases the reduction in urinary phosphorus excretion in rats. Animal Model: Rats (intestinal loop model) Dosage: 0.15, 0.5 mg/kg Administration: P.o. Result: Reduced passive paracellular phosphate absorption by reduced urinary phosphate and sodium excretion after the high-phosphate meal and increased sodium and phosphate delivery to the cecum. Animal Model: 8 weeks, 250 g male Sprague–Dawley rats Dosage: 0.15 mg/kg in combination with sevelamer (0%, 0.75%, 1.5%, and 3% (wt/wt)) Administration: Oral gavage; twice-daily for 11 consecutive days Result: Significantly augmented the reduction in urinary phosphorus excretion.
  • 參考文獻(xiàn):
    1. King AJ, et al. Inhibition of sodium/hydrogen exchanger 3 in the gastrointestinal tract by tenapanor reduces paracellular phosphate permeability. Sci Transl Med. 2018 Aug 29;10(456):eaam6474. 2. King AJ, et al. Combination treatment with tenapanor and sevelamer synergistically reduces urinary phosphorus excretion in rats. Am J Physiol Renal Physiol. 2021 Jan 1;320(1):F133-F144.
  • 溶解性: soluble  in  DMSO
  • 保存條件: -20℃
  • 配置溶液濃度參考:
    1mg 5mg 10mg
    1 mM 0.873 ml 4.367 ml 8.733 ml
    5 mM 0.175 ml 0.873 ml 1.747 ml
    10 mM 0.087 ml 0.437 ml 0.873 ml
    50 mM 0.017 ml 0.087 ml 0.175 ml
  • 注意:部分產(chǎn)品我司僅能提供部分信息,我司不保證所提供信息的權(quán)威性,僅供客戶參考交流研究之用。
  • 提示:詳情請(qǐng)下載說明書。
  • 產(chǎn)品描述: Tenapanor (AZD1722) is a potent and orally active sodium/hydrogen exchanger isoform 3 (NHE3) inhibitor. Tenapanor reduces intestinal phosphate absorption predominantly through reduction of passive paracellular phosphate flux. Tenapanor has the potential for the research of hyperphosphatemia
  • 靶點(diǎn): IC50: 5 nM (NHE3, human), 10 nM (NHE3, rat);SodiumChannel
  • 體內(nèi)研究:
    Tenapanor (0.15, 0.5 mg/kg; p.o.) reduces passive paracellular phosphate absorption in rats. Tenapanor (0.15 mg/kg; p.o.; twice-daily for 11 consecutive days) increases the reduction in urinary phosphorus excretion in rats. Animal Model: Rats (intestinal loop model) Dosage: 0.15, 0.5 mg/kg Administration: P.o. Result: Reduced passive paracellular phosphate absorption by reduced urinary phosphate and sodium excretion after the high-phosphate meal and increased sodium and phosphate delivery to the cecum. Animal Model: 8 weeks, 250 g male Sprague–Dawley rats Dosage: 0.15 mg/kg in combination with sevelamer (0%, 0.75%, 1.5%, and 3% (wt/wt)) Administration: Oral gavage; twice-daily for 11 consecutive days Result: Significantly augmented the reduction in urinary phosphorus excretion.
  • 參考文獻(xiàn):
    1. King AJ, et al. Inhibition of sodium/hydrogen exchanger 3 in the gastrointestinal tract by tenapanor reduces paracellular phosphate permeability. Sci Transl Med. 2018 Aug 29;10(456):eaam6474. 2. King AJ, et al. Combination treatment with tenapanor and sevelamer synergistically reduces urinary phosphorus excretion in rats. Am J Physiol Renal Physiol. 2021 Jan 1;320(1):F133-F144.
  • 溶解性: soluble  in  DMSO
  • 保存條件: -20℃
  • 配置溶液濃度參考:
    1mg 5mg 10mg
    1 mM 0.873 ml 4.367 ml 8.733 ml
    5 mM 0.175 ml 0.873 ml 1.747 ml
    10 mM 0.087 ml 0.437 ml 0.873 ml
    50 mM 0.017 ml 0.087 ml 0.175 ml
  • 注意:部分產(chǎn)品我司僅能提供部分信息,我司不保證所提供信息的權(quán)威性,僅供客戶參考交流研究之用。
輸入產(chǎn)品批號(hào):

本計(jì)算器可幫助您計(jì)算出特定溶液中溶質(zhì)的質(zhì)量、溶液濃度和體積之間的關(guān)系,公式為:


質(zhì)量 (mg) = 濃度 (mM) x 體積 (mL) x 分子摩爾量 (g/mol)


  • =
    *
    *


源葉所有產(chǎn)品僅用作科學(xué)研究,銷售產(chǎn)品行為均適用于我司網(wǎng)上所列通用銷售條款。
点击收缩